Vimarsana
Biggest News Aggregation in the World

Page 2 - John Teerlink News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Teerlink. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Teerlink Today - Breaking & Trending Today

Experimental heart failure drug has little impact on exercise tolerance - Vimarsana News

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

Investigational Drug for Heart Failure has Little Impact on Exercise Tolerance - Vimarsana News

Investigational Drug for Heart Failure has Little Impact on Exercise Tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t

Woody Paige: Passing of Greg Robinson gives Broncos another fallen hero - Vimarsana News

Woody Paige: Passing of Greg Robinson gives Broncos another fallen hero

I’m running out of words and tears.

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs - Vimarsana News

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021 When omecamtiv mecarbil is used in patients who have chronic heart failure with reduced ejection fraction (HFrEF), the greater beneficial impact on clinical outcomes is seen in those with lower ejection fractions, a secondary analysis of the placebo-controlled GALACTIC-HF trial shows. Among the prespecified subgroups in the trial, LVEF was the strongest modifier of the treatment effect, with larger reductions in the risk of HF events or CV death observed as values fell ( P = 0.004 for interaction). Reductions in NT-proBNP were greater at the lower end of the range, as well, John ...

Source: tctmd.com
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript - Vimarsana News

Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript

Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for questions-and-answers after the presentation. I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead. Diane Weiser -- Senior Vice President of Corporate Communications & Investor Relations Good afternoon...

Source: fool.com